Owner Scorecard


← All companies ← ITUB Manual IX → ← IRWD Pharmaceuticals IXHL →

IVA, Inventiva S.A.

Pharmaceuticals consumer brand UnprofitableDistress / turnaround

We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of MASH.

Currently, lanifibranor is our only product candidate in development.

Latest annual: FY2024 20-F · figures as filed, in EUR · 1 ADS = 1 ordinary share
IVA · Inventiva S.A.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2024
€14M
−22.1% YoY · 14% 5-yr CAGR
Vital signs · TTM
Cash & investments €122M
Cash burn · annual €91M
Runway 1.3 yrs

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No meaningful revenue yet; the record is the cash on hand against the burn. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
What moves the needle
Operating margin has run around −1029% through the cycle, the operating line deeply negative — so the lever is the path to a margin at all: revenue growth against the cost curve and the cash runway, not the level of a margin that isn't there yet. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2018–2024

realized figures from each filing · older years to the left
2018’182019’192020’202021’212022’222023’232024’24TTMTTMJun 2025
Income statement
€3M€7M€372K€4M€12M€17M€9M€14MRevenueRevenue
(€33M)(€30M)(€30M)(€52M)(€57M)(€103M)(€98M)(€108M)Operating incomeOp. inc.
n/m−433.2%n/mn/m−468.9%−587.7%n/m−795.3%Operating marginOp. mgn
(€33M)(€30M)(€34M)(€50M)(€54M)(€110M)(€184M)(€311M)Net incomeNet inc.
Cash flow & returns
(€34M)(€28M)(€31M)(€48M)(€45M)(€82M)(€86M)(€91M)Operating cash flowOp. cash
(€1M)€2M€3M€2M€9M€29M€98M€220MWorking capital & otherWC & other
-54%-73%-30%-56%-119%Return on equityROE
−54%−73%−30%−56%−119%Retained to equityRetained/eq
Balance sheet
€57M€36M€106M€87M€87M€27M€97M€122MCash & investmentsCash+inv
€6K€4K€48K€4M€0€4M€531K€11MReceivablesReceiv.
€410K€387K€320K€392K€373K€417K€0€0InventoryInvent.
€7M€7M€15M€19M€38M€33M€35MAccounts payablePayables
€416K(€7M)(€7M)(€10M)(€19M)(€33M)(€32M)(€24M)Operating working capitalOper. WC
€72M€49M€133M€116M€106M€48M€112M€173MCurrent assetsCur. assets
€15M€14M€14M€23M€31M€50M€121M€58MCurrent liabilitiesCur. liab.
4.7×3.5×9.6×5.1×3.5×1.0×0.9×3.0×Current ratioCurr. ratio
€80M€57M€139M€122M€116M€70M€119M€179MTotal assetsAssets
-130.1×-374.2×-5.0×-19.8×-27.1×-14.9×-1.1×-0.5×Interest coverageInt. cov.
€62M€41M€111M€89M€45M(€32M)(€107M)(€9M)Shareholders’ equityEquity
Per share
20.5M23.5M33.9M39.2M41.4M45.4M59.8M139MShares out (diluted)Shares
€0.16€0.30€0.01€0.11€0.29€0.39€0.15€0.10Revenue / shareRev/sh
€-1.61€-1.28€-0.99€-1.27€-1.31€-2.43€-3.08€-2.24EPS (diluted)EPS
€3.00€1.76€3.28€2.27€1.10€-0.71€-1.78€-0.06Book value / shareBVPS

The diluted share count moved ×1.44 into 2020 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×2.33 into TTM — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The record, charted

FY2018–2024

Each measure over its full record; the current point and the worst year marked.

Share count
60Mpeak FY2024
III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2024 20-F · source on SEC EDGAR →

Will it survive?

  • Does not cover its interest
    Operating income (€108M) ÷ interest expense €199M
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • Debt under-captured — leverage unknown, not low
    What this means

    This company pays far more interest than its tagged debt implies (the rest sits under segment dimensions the data source strips), so its net cash or net debt cannot be read honestly: the gap is unknown, not zero, and 'net cash' here would be exactly the fiction the figure is meant to prevent. Judge it on the record and owner earnings instead.

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Is it a good business?

  • Debt under-captured
    Industry peers: median -85%
    What this means

    This company's interest bill implies far more debt than its filings tag at the consolidated level (the rest sits under segment dimensions the data source strips), so invested capital, and the return on it, cannot be read honestly. Judge this one on Owner Earnings and the record instead.

  • Not enough data
    Industry peers: median -530%
    What this means

    The filing data didn't include the inputs for this check.

  • Loss, and burning cash
    Net income (€311M) · cash from operations (€91M)
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting?
    Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Graham’s defensive tests · 1 of 3 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size
    Revenue ≥ $2B (a dollar floor) · €14M
    What this means

    Big enough to weather a storm. Graham's floor is a dollar figure — about $2B of revenue as a conservative modern stand-in. This company reports in its home currency and we carry no exchange rate, so we show the figure and leave the size bar for you to apply rather than convert it with a number we don't have.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 2.96×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt
    Debt ≤ working capital ·
    What this means

    The filings tag only a fraction of the debt this company's interest bill implies (much of it sits under segment dimensions the data source strips), so this test can't be run honestly.

  • Earnings stability Miss
    A profit every year (7-yr record) · 7 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Miss
    Uninterrupted dividends · none paid
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are €-0.60/share (latest year €-1.61), the averaged base the calculator's gate runs on, and book value is €-0.05/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2018–2024

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 0 of 7
    What this means

    Lost money in 7 year(s), look at what happened there before trusting the average.

  • Operating margin −3150% → −706% (3-yr avg ends)

    In the filing’s words The record and the words agree: the margin widened and the filing attributes the gain to its own pricing, not volume alone.

    What this means

    Through the cycle the operating margin widened — about −3150% early to −706% lately, median −1029% — pricing power intact or improving.

  • Worst year 2020 · −7988.7% op. margin
    What this means

    Operations went underwater in 2020, understand why before trusting the good years.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

In its own filing Raised, but not as a competitor

The filing raises AI among its risks, but in other terms (security, regulation, energy or the like), not as a competitor to its product.

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of fiscal year-end, Jun 30, 2025

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets€173M
  • Cash & short-term investments€122M
  • Receivables€11M
  • Other current assets€40M
Current liabilities€58M
  • Debt due within a year€18K
  • Accounts payable€35M
  • Other current liabilities€24M
Current ratio2.96×all current assets ÷ what's due · Graham looked for 2×
Quick ratio2.96×stricter: inventory excluded
Cash ratio2.09×strictest: cash alone against what's due
Working capital€114Mthe cushion left after near-term bills
Debt due this year vs. cash€18K due · €122M cash covered by cash on hand, no refinancing forced · both figures from the Jun 30, 2025 balance sheet
Cash runway1.3 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Deeper floors
Tangible book value(€9M)equity stripped of goodwill & intangibles
Net current asset value(€15M)Graham's net-net: current assets less all liabilities
Debt incl. operating leases€35M€4M of it operating leases

From the company's latest filing.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
QUREuniQure N.V.$16M94%-611.9%-87%-605%
IRDOpus Genetics Inc.$14M99%-205.8%-248%
ABUSArbutus Biopharma Corporation$14M-936.4%-85%-685%
IVAInventiva S.A.€14M-1029.2%-396%
EVMNEvommune Inc.$13M-623.6%-40%-590%
PRLDPrelude Therapeutics Incorporated$12M-861.3%-247%-464%
CBIOCrescent Biopharma Inc.$11M-957.2%-530%
XOMAXOMA Royalty Corporation$10M-177.6%-16%-250%
Group median-742.5%-86%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Enter the US price, in dollars: the NYSE/Nasdaq quote you hold. Per the filing's own cover, “American Depositary Shares, each representing one ordinary”; Inventiva S.A. reports in EUR, so every figure in this tool is stated per ADS and translated at EUR 1 = $1.145 (2026-07-17, reference rate) so your dollar quote reconciles exactly. The record tables elsewhere on this page remain as filed, in EUR.

The owner-earnings base could not be formed from this filing’s tagged data (operating cash flow or capital spending is missing), so the owner-earnings reverse-DCF has no base to grow. We read the price from both ends instead: type a price to see the profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Revenue, delivered22%/yr’19→’24

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "Inventiva S.A. (IVA), the owner's record," https://ownerscorecard.com/c/IVA, data as of 2026-07-09.

Manual order: ← ITUB its page in the Manual IX →

Industry order: ← IRWD the Pharmaceuticals chapter IXHL →